The MCC / TRI / Covance RBQM Interview

In this free podcast, Keith Dorricott from the MCC interviews Duncan Hall, CEO TRI, and Kristin Stallcup, Senior Director Covance, about all things Risk-Based Quality Management.  In this fascinating hour-long interview, they cover a wide range of topics, including KRIs, QTLs, evolving technology, the Big Data challenge and measuring success. Split into eight easy-to-listen-to sections, Keith explores the issues…

Read More

CEO Blog

CBI RBM 2019 Reflections Part 3 of 3 – Predictions for 2020 Reflecting on RBQM in 2019, and not just at the CBI conference, I am struck by how the RBQM conversations I’m having are turning quickly from “why” to “how”.  In 2020 we’ll see a much greater focus on implementation and the ‘operationalizing’ of RBQM and the rise…

Read More

COO’s Blog

January 2020 ICH E6 R3 – what next? At the end of 2019, the ICH Management Committee endorsed the business plan and scope for ICH E6 R3.  A complete re-write of E6 is being proposed, focusing on two areas: Appendix 1 – Interventional Trials; and Appendix 2 – Non-Interventional Trials. The draft technical document for Appendix 1 is expected…

Read More

FDA RBM Q&A Guidance for Industry

In March 2019 the FDA released their RBM Q&A Guidance for Industry. If you haven’t read it yet, the link is below, it makes for some interesting reading. The focus of this guidance is to provide further clarification and suggestions on how best to implement risk based approaches to monitoring. Interestingly the guidance focuses very heavily on the risk…

Read More

The R2 story – what is it, why it’s needed & why now?

Lots of people don’t understand what R2 is and why it’s needed. And unless you understand the fundamental reasons for its creation and adoption, it’s easy to dismiss it as ‘just more bureaucracy’.  But it isn’t.  It’s much more important than that, and here’s the reasons why. The way clinical trials are conducted has changed dramatically over the last…

Read More

Veristat partners with TRI

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients Veristat, a full-service Clinical Research Organization (CRO), announced today that it has partnered with Triumph Research Intelligence (TRI), a global leader providing technology and solutions for centralized and risk-based monitoring (RBM) to improve clinical trial quality and compliance. Earlier this year, the US Food…

Read More

Phil M’Caw new TRI CFO

Phil M’Caw has been appointed as the new Chief Financial Officer of TRI. Phil has over 25 years of hands-on experience of financial and commercial management in several sectors with growth businesses having international footprints. He trained as Chartered Accountant with KPMG London before moving into management consultancy with KPMG and then into roles in industry. He has worked…

Read More

Mike Lewis announced as Chair of TRI

Mike is Chair of 4 public and private healthcare companies and has 30 years global Health industry experience having previously held senior roles at Align Technology (Amsterdam), Boston Scientific (Paris), C.R. Bard (USA), Sybron (Switzerland) and Becton Dickinson (UK) and was President of Gambro (Sweden) leading the £3bn buyout. Having spent 22 of the last 25 years living and…

Read More

TRI raises multi-million growth funding

TRI raises multi-million growth funding from Octopus Investments to expand its Risk-Based Monitoring platform for clinical trials 15th October 2018, LONDON, UK – TRI, a leading global provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has completed a growth capital fundraise to accelerate development of its core technology platform, OPRA and expand its international presence. Founded in 2014,…

Read More

The best questions from 3 years of webinars and training

Over the past three years we’ve trained over 1,000 people in webinars, on-line training sessions and face-to-face sessions.  Most of that training has been done by Tammy Finnigan, our COO.  She’s the person ‘on the hook’ to answer when someone asks a difficult question.  Fortunately for us, she has a wealth of experience in Quality Management, Risk Based Monitoring,…

Read More

TRI and Wider Perspectives Partner on ICH GCP E6 Rev 2

As the implementation of ICH GCP E6 Rev 2 (referred to as ‘Rev 2’) draws closer (current best guess is November this year) the need to understand, plan for and become compliant with the new guideline grows stronger. In order to help industry as a whole, and individual companies specifically to tackle this challenge, TRI and Wider Perspectives have…

Read More